Date: 2011-07-05
Type of information: Development agreement
Compound: microsphere-based formulation
Company: Octoplus (The Netherlands) undisclosed Danish pharmaceutical company
Therapeutic area: undisclosed
Type agreement: sevelopment
production
Action mechanism:
Disease: undisclosed
Details: OctoPlus has signed a process development and manufacturing contract with a pharmaceutical company headquartered in Denmark. The undisclosed contract value will make a material contribution to OctoPlus\' annual revenues.
Financial terms: Financial details were not disclosed.
Latest news:
